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Background:  Based on clinical trial results, the WHO recommends infant HIV testing at age 4-
6 weeks and immediate antiretroviral therapy (ART) initiation in all HIV-infected infants. Little is 
known about the outcomes of HIV infected infants diagnosed with HIV in the first weeks of life in 
resource-limited settings. We assessed ART initiation and mortality in the first year of life among 
infants diagnosed with HIV by 12 weeks of age. 
Methods:  Cohort of HIV-infected infants in Kinshasa and Blantyre diagnosed before 12 weeks 
to estimate 12-month cumulative incidences of ART initiation and mortality, accounting for 
competing risks. Multivariate models were used to estimate associations between infant 
characteristics and timing of ART initiation.  
Results: 121 infants were diagnosed at a median age of 7 weeks (interquartile range 6-8). The 
cumulative incidence of ART initiation was 46% (95% CI: 36%, 55%) at 6 months and 70% 
(95% CI: 60%, 78%) at 12 months. Only age at HIV diagnosis was associated with ART 
initiation by age 6 months, with a subdistribution hazard ratio of 0.70 (95% CI: 0.52, 0.91) for 
each week increase in age at DNA PCR test. The 12-month cumulative incidence of mortality 
was 20% (95% CI: 13%, 28%). 
Conclusions: Despite early diagnosis of HIV, ART initiation was slow and mortality remained 
high, underscoring the complexity in translating clinical trial findings and WHO guidance into 
real-life practice. Novel and creative health system interventions will be required to ensure that 
all HIV infected infants achieve optimal treatment outcomes under routine care settings. 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
3 
 
INTRODUCTION 
Morbidity and mortality among untreated HIV-infected children is exceptionally high,1,2 
with almost 50% of perinatally-infected children estimated to die within the first year of life and 
20% estimated to die within the first three months of life.1 Early initiation of antiretroviral 
therapy (ART) has been shown to significantly reduce the risk of mortality. In a landmark 
clinical trial (CHER study), asymptomatic infants (median age 7.4 weeks) with a CD4% >25 
who were randomized to immediate ART experienced a large (75%) reduction in mortality 
compared to infants who were randomized to initiate ART based on immunologic or clinical 
eligibility criteria.3 The World Health Organization (WHO) amended the guidelines in 2008 to 
recommend immediate initiation of ART in all children diagnosed with HIV in the first two 
years of life, independent of clinical and immunologic markers of immunosuppression.4 
Translating evidence from clinical trials into practice and achieving similar results in 
routine care settings can be difficult, particularly in resource-limited settings. Although the roll-
out of ART has been dramatic, the treatment of HIV-infected infants in sub-Saharan Africa has 
lagged behind that of older children and adults. In 2014, overall, only 32% of HIV-infected 
children were accessing antiretroviral treatment compared to 41% of eligible adults.5 Timely 
initiation of ART for perinatally-infected infants is particularly challenging, in large part due to 
the complexity of early infant HIV diagnosis (EID) at four to six weeks of age.4,6 Several barriers 
to accessing EID have been highlighted in prior studies, including cultural resistance to testing, 
lack of laboratory infrastructure, weak sample transport networks, poor communication between 
laboratories and primary care clinics, weak linkages between EID and pediatric HIV care and 
treatment programs, non-availability of pediatric-appropriate antiretroviral formulations, and loss 
to follow-up at all stages of the EID cascade, including between delivery and testing.7-10  
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Little is known about the outcomes of HIV-infected infants diagnosed through EID in 
resource-constrained settings. Using data from two HIV research and treatment programs in the 
Democratic Republic of Congo (DRC) and Malawi, we assessed early infant ART (EIART) 
initiation and mortality in the first year of life among infants diagnosed with HIV prior to 12 
weeks of age.  
MATERIALS AND METHODS 
Study population  
The study population included HIV-infected infants diagnosed with HIV following EID 
performed prior to 12 weeks of age in Blantyre, Malawi (between July 2008 and August 2011) 
and Kinshasa, Democratic Republic of Congo (DRC) (between August 2009 and August 2012). 
In Blantyre, EID activities were implemented as part of a research study that assessed the 
effect of HIV on the neurodevelopment. HIV-exposed infants identified through prevention of 
mother-to-child transmission (PMTCT) activities at two public health facilities were referred to 
study staff for EID services. HIV-infected infants were referred back to the primary care facility 
for clinical management and ART initiation. The Kinshasa data come from two centralized HIV 
prevention, care and treatment sites (one primary health center and one pediatric hospital) 
providing family-centered care.  The referral network for the two centralized sites includes 90 
maternities providing routine PMTCT services.  HIV-exposed infants were identified through 
routine PMTCT activities.  Before 2011, all HIV-exposed infants were referred for EID and 
clinical management at one of the two centralized sites.  In the decentralized model implemented 
in 2011, all ART eligible pregnant women and their exposed infants were referred to a 
centralized site for care, while women not yet eligible for ART had the option of receiving EID 
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for their exposed infants at the level of the maternity with referral for care to a centralized site if 
their infant was HIV-infected.11-14    
Available PMTCT services in Malawi consisted of single dose nevirapine before July 
2009. Between July 2009 and January 2010 the regimen changed to include zidovudine from 28 
weeks of gestation until a week after delivery, with the addition of nevirapine for the week 
following delivery. After delivery, single dose nevirapine was given to the infant within 72 hours 
and zidovudine was given for seven days. In the DRC, before 2010 mothers who were not yet 
eligible for ART received single dose nevirapine, as did their infants. Once the national 
guidelines changed to include Option A in 2010, the regimen changed to zidovudine prophylaxis 
from as early as 14-weeks gestation up to seven days postpartum, with infants receiving a daily 
prophylactic regimen of nevirapine from birth until six weeks after weaning or for six days after 
birth if they were not breastfed. Due to inconsistent availability of zidovudine and presentation to 
care later in pregnancy, some women continued to receive single dose nevirapine on its own or 
in addition to zidovudine even after 2010.  
In both cities, EID was performed using DNA PCR (version 1.5 of the Amplicor HIV-1 
DNA test kit, Roche, Basel, Switzerland) on dried blood spots (DBS) collected via heel prick. In 
Blantyre, confirmatory testing was done by DNA PCR on a second blood spot of the original 
DBS card or by an HIV RNA viral load test (version 1.5 of the Amplicor HIV-1 Monitor, Roche) 
on a subsequently collected peripheral blood sample. In Kinshasa, confirmatory testing was done 
by DNA PCR on a new DBS sample. An infant was considered HIV-infected if the confirmatory 
test was also positive.  In accordance with the 2008 WHO guidelines,4 all HIV-infected infants 
under two years of age were eligible to receive ART (standard of care during study period was 
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nevirapine/stavudine/lamivudine in Malawi and  zidovudine/lamivudine/lopinavir/ritonavir or 
zidovudine/lamivudine/nevirapine in the DRC). 
The study was approved by the Institutional Review Board of the University of North 
Carolina at Chapel Hill, the Ethics Committee of the Kinshasa School of Public Health, and the 
University of Malawi College of Medicine Review Board. Parents or guardians of all children 
included in the analysis provided written informed consent. 
Measurements 
The primary outcomes of interest were ART initiation and mortality in the first 12 
months of life. Covariates included age at first infant HIV test, gender, receipt of any PMTCT 
prophylactic regimen (based on current recommendations) by infant and/or mother, and 
breastfeeding status (exclusive breastfeeding or not), maternal ART status, severity of 
immunodeficiency (CD4%<25 or ≥25), anemia, and growth failure measured at time of infant 
HIV diagnosis. The hemoglobin cut points for severe, moderate, and mild anemia were defined 
according to the WHO recommendations for children under five (<7 g/dl, 7-9.9 g/dL, and 10-
10.9 g/dL, respectively).15 Growth failure was defined as having a weight-for-age z-score 
(underweight) or height-for-age z-score (stunted) less than two standard deviations for the weight 
and height measured between HIV diagnosis and 17 weeks of age. Z-scores were derived from 
the WHO Child Growth Standards16. Severity of immunodeficiency and anemia were determined 
from the first available CD4% and hemoglobin values measured before 15 weeks of age.  
Statistical analysis 
Descriptive statistics were used to characterize the study population at infant enrollment 
and at age 12 months. Competing risk cumulative incidence functions17 were computed to 
estimate the 12-month cumulative incidence of infant ART initiation, stratified by city. Infants 
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contributed follow-up time from birth until the event of interest (ART initiation), competing 
event (death), or censoring event (loss to follow-up [LTFU], transfer out, 12 months of age, or 
end of data collection (August 2013 for Kinshasa, no administrative censoring for Blantyre), 
whichever occurred first. Infants were considered LTFU on their last attended clinic visit date 
following two (Blantyre) or three (Kinshasa) failed tracking attempts after a missed appointment. 
The same approach was used to estimate 12-month cumulative incidences of death, except there 
were no competing risks to account for.   
To determine predictors of ART initiation by six months of age, we used the SAS macro 
%PSHREG18 to implement the proportional subdistribution hazards model of Fine and Gray.17,19 
Bivariate and multivariate subdistribution hazard ratios (in text referred to as HR), as well as 
corresponding 95% confidence intervals (CI), were generated. In these analyses, infants 
contributed follow-up time from birth until the event of interest (ART initiation by age six 
months, a competing event (death), or a censoring event (LTFU, transfer of care to another 
facility, six months of age, or end of data collection), whichever occurred first. 
All analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina). 
We conducted a complete case analysis, excluding observations with missing values for 
covariates. All tests of statistical significance were two-sided and the threshold for statistical 
significance was p < 0.05. 
RESULTS 
Between 2008 and 2012, 2593 children underwent DNA PCR testing at the EID 
programs: 1305 at the two centralized HIV care and treatment sites in Kinshasa and 1288 in the 
Blantyre clinics. Of these children, 121 (4.7%) were diagnosed with HIV by age 12 weeks of 
age: 38 (2.9%) in Kinshasa and 83 (6.4%) in Blantyre.  Median age at HIV diagnosis for these 
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121 children was seven weeks (interquartile range: 6-8 weeks) and similar between the two 
countries (Table 1).  
Despite the availability of routine PMTCT services, in 16% (18) of infants (9% (3) in 
Kinshasa and 19% (15) in Blantyre) neither the mother nor the infant had received any 
antiretroviral drugs for PMTCT (Table 1). Overall, 8% (9) of women were receiving 
antiretroviral treatment. At time of HIV diagnosis, 80% (94) of infants were exclusively 
breastfed, 21% (23) were underweight, and 34% (36) were stunted. About half of all infants had 
a CD4% below 25 (63% (17) in Blantyre and 43% (15) in Kinshasa), but CD4% was not 
available for all infants in Blantyre.  
During the first 12 months of life, 75 (62%) children initiated ART. ART was initiated at 
a median age of 6.2 months (27 weeks, range 9.1 to 51.4 weeks), at a younger age in Kinshasa 
(24 weeks) than Blantyre (33 weeks) (Figure 1). The 12-month cumulative incidence of ART 
initiation was 70% (95% CI 60%, 78%), and was higher in Kinshasa (82%, 95% CI: 64%, 92%) 
than Blantyre (64%, 95% CI: 51%, 74%) (p=0.017). The 6-month cumulative incidence of ART 
initiation was 46% (95% CI 36%, 55%), and was also higher in Kinshasa (54%, 95% CI: 37%, 
69%) than in Blantyre (42%, 95% CI: 30%, 53%) (p=0.12). Of the 46 infants who did not start 
ART in the first 12 months of life, 17 (40.0%) died and 15 (32.6%) were LTFU.  
In bivariate analysis (Table 2), age at HIV diagnosis (p=0.02) was predictive of ART 
initiation by six months of age, with a hazard ratio of 0.79 (95% CI: 0.65, 0.95) for each week 
increase in age at DNA PCR test. Country, gender, exclusive breastfeeding, receipt of infant or 
maternal antiretrovirals for PMTCT, and underweight status of the child were not associated with 
timing of ART initiation. In multivariate analysis (Table 2), age at DNA PCR test remained 
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independently associated (p<0.01) with ART initiation by six months of age (HR, 0.70; 95% CI: 
0.52, 0.91). 
Overall, 11% (95% CI: 6%, 18%) of infants died by six months of age and 20% (95% CI: 
13%, 28%) died by 12 months of age (Figure 2). Mortality in the first year of life was higher in 
Blantyre than in Kinshasa with a 12-month cumulative incidence of 27% (95% CI: 17%, 39%) in 
Blantyre versus 8% (95% CI: 2%, 20%) in Kinshasa (p=0.04).  
DISCUSSION 
Among infants diagnosed with HIV in the first 12 weeks of life in Blantyre, Malawi and 
Kinshasa, DRC, we found that few children received immediate ART, a high proportion failed to 
initiate ART by six months of age, and one in five infants died before reaching one year of age.  
The association between earlier DNA PCR testing and earlier ART initiation in our 
analysis highlights the importance of removing barriers to EID, including inadequate recording 
of HIV exposure and maternal HIV status on patient records, maternal non-disclosure, 
insufficient awareness of EID, high cost and logistical complexity of HIV DNA PCR tests, and 
LTFU after diagnosis given the need for a return visit. Development of an accurate, cheap point-
of-care assay for EID has the potential to optimize the outcome of perinatally-infected infants.  
During the pre-ART era, when an estimated 36% of perinatally-infected children died 
within the first year of life,20 findings of retrospective cohort studies observed that starting ART 
in the first six to 12 months of life decreases mortality and improved clinical outcomes.21-24 Our 
results extend these finding by assessing the one year outcomes in infants participating in a 
PMTCT-linked EID program. While the 20% mortality rate we observed in the first year of life 
among infants diagnosed with HIV at a median age of 7 weeks (IQR 6-8) is an improvement 
compared to the pre-ART era, it is much higher than the mortality observed in infants 
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randomized to immediate ART in the CHER study (4% over a median follow-up of the full 
cohort of 40 weeks) conducted in South Africa. We believe the discrepancy between the trial and 
implementation data is due to several factors. First, the CHER study excluded children with 
evidence of immunosuppression (CD4% <25). Similar to observations in other studies23, we 
found that half (52%) of young infants already have signs of immunosuppression at time of 
infant HIV diagnosis. Expanding eligibility for immediate ART to all infants, including those 
with immunosuppression in the first weeks of life, will result in higher mortality rates than what 
was observed in the restricted trial population. Another important difference is the median age of 
ART initiation. Under the CHER trial conditions, all children were tested for HIV prior to age 6 
weeks and ART initiation was achieved by age 7.4 weeks (IQR: 6.6, 8.9).3 In our analysis, we 
included children receiving EID before age 12 weeks to take into account of the delays that often 
occur under real world conditions. In this population, ART initiation occurred at a median age of 
6.2 months. Delays in ART initiation occur as children need to return for their EID HIV test 
result, which is often delayed given the difficulties with transportation and communication 
between the centralized laboratory and the primary care clinics. Furthermore, upon diagnosis, 
children often need to be referred for ART initiation as this is not yet available at primary care in 
many settings, again resulting in further delays.  
While the delays in ART initiation were present in both cities, rates of ART initiation 
were higher and 12-month mortality was lower in Kinshasa compared to Blantyre, with no 
deaths occurring between 3-12 months in the Kinshasa patients, likely due in part to higher ART 
initiation rates. While the numbers are relatively small and theses differences need to be 
confirmed, the differences may be explained by the fact that the HIV care and treatment program 
in Kinshasa received a high level of international financial and technical assistance, including 
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intensive monitoring and evaluation, whereas HIV-infected infants in Blantyre were referred to 
routine  public HIV care and treatment program. Furthermore, a strong family-centered program, 
which was the focus of the Kinshasa program, has been shown to result in improved infant 
outcomes.14 We envision that the shift to Option B+ in Malawi and DRC may result in improved 
infant HIV care and treatment25 by overcoming some of the barriers to timely ART initiation 
including stigma,26,27 loss to follow up, 28-30 and fear of finding out an infant’s status.26,27  There 
is existing evidence that increasing access to combination antiretroviral therapy for mothers 
results in improved retention of HIV-exposed infants,14  a finding which may be promising for 
improved linkage to care and retention of infants born to HIV-infected mothers in the setting of 
Option B+.  
The use of prospectively collected data on infants diagnosed at two different resource-
poor settings are important strengths of this assessment of infant outcomes which, to our 
knowledge, is the first report of infant outcomes under routine PMTCT and EID implementation 
at primary care. It is estimated that in 2014 a quarter of women still did not have access to any 
PMTCT regimens. 5 Our data provide valuable context for the reality and challenges of 
implementing HIV prevention and treatment in the real world setting. The challenges 
encountered in the settings described here have relevance for the implementation a wide variety 
of current and future public health guidelines that go beyond the specific EID guidelines that are 
the focus of this work. Several limitations should be noted. First, despite the aggregation of two 
databases, the limited sample size prohibited assessment of the causal effect of timing of ART on 
mortality. Furthermore, due to delays in availability of test results and the need for referral for 
HIV care and ART, some children were lost to follow up and others died before ART could be 
initiated. In the analysis, we tried to take this into account by treating death as a competing risk.  
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Figure Legend 
Figure 1. Twelve-month cumulative incidence of ART initiation in Kinshasa, Democratic 
Republic of Congo and Blantyre, Malawi  
 
Figure 2. Twelve-month cumulative incidence of death in Kinshasa, Democratic Republic 
of Congo and Blantyre, Malawi  
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TABLE 1. Characteristics of 121 HIV-infected infants at enrollment 
 Overall  Blantyre Kinshasa p-valuea 
 (N=121) (N=83) (N=38)  
Age in weeks at first DNA PCR 
test, median (IQR) 
7 (6-8) 7 (6-8) 7 (6-8) 0.07 
Gender, N (%)    0.42 
F 70 (58) 46 (55) 24 (63)  
M 51 (42) 37 (45) 14 (37)  
Exclusive breastfeeding, N (%)    0.28 
No 23 (20) 14 (17) 9 (26)  
Yes 94 (80) 68 (83) 26 (74)  
Missing 4 1 3  
Infant or maternal PMTCT 
regimen, N (%) 
   0.20 
No 18 (16) 15 (19) 3 (9)  
Yes 95 (84) 65 (81) 30 (91)  
Missing 8 3 5  
Maternal ART, N (%)    0.02 
No 110 (92) 78 (96) 32 (84)  
Yes 9 (8) 3 (4) 6 (16)  
Missing 2 2 0  
CD4%, N (%)    0.12 
25+ 30 (48) 10 (37) 20 (57)  
<25 32 (52) 17 (63) 15 (43)  
Missing 59 56 3  
Stunted, N (%)    0.93 
No 71 (66) 46 (67) 25 (66)  
Yes 36 (34) 23 (33) 13 (34)  
Missing 14 14 0  
Underweight, N (%)     
No 85 (79) 59 (84) 26 (68) 0.05 
Yes 23 (21) 11 (16) 12 (32)  
Missing 13 13 0  
Anemia, N (%)    0.07 
Normal 13 (20) 8 (20) 5 (21)  
Mild 13 (20) 9 (23) 4 (17)  
Moderate 30 (47) 15 (38) 15 (63)  
Severe 8 (13) 8 (20) 0 (0)  
Missing 57 43 14  
a
 p-Values are for the comparison of Blantyre versus Kinshasa. 
 
Note:  Enrollment characteristics were measured by 15 weeks of age, except for weight and 
height, which were measured by 17 weeks of age.  Analysis includes first available 
measurement for each child. 
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TABLE 2. Predictors of ART initiation by six months of age 
 
Subdistribution hazard ratio 
(95% confidence interval) p-Value 
Bivariate Analysis 
  
Kinshasa vs. Blantyre 1.58 (0.88, 2.74) 0.12 
Each week increase in age at PCR test 0.79 (0.65, 0.95) 0.02 
Female vs. Male 1.36 (0.78, 2.46) 0.29 
Exclusive breastfeeding vs. Not 0.97 (0.50, 2.05) 0.93 
CD4% <25 vs. 25+ 0.77 (0.37, 1.55) 0.45 
Any PMTCT regimen v None 0.92 (0.44, 2.23) 0.45 
Maternal ART vs. No maternal ART 1.06 (0.32, 2.60) 0.91 
Underweight vs. Not 1.00 (0.48, 1.89)   0.99 
 
 
Multivariate Analysis* 
  
Kinshasa vs. Blantyre 1.57 (0.78, 3.07) 0.21 
Each week increase in age at PCR test 0.70 (0.52, 0.91) 0.01 
Female vs. Male 1.46 (0.77, 2.90) 0.27 
Exclusive breastfeeding vs. Not 0.60 (0.28, 1.41) 0.14 
Any PMTCT regimen vs. None 0.86 (0.37, 2.34) 0.76 
Underweight vs. Not 1.40 (0.59, 3.07) 0.43 
Due to the high frequency of missing CD4 data, this variable was not included in the multivariate 
analysis 
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 Gray’s Test for Equality of Cumulative 
Incidence Functions p=0.02 
Figure 1
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 Gray’s Test for Equality of Cumulative 
Incidence Functions p=0.04 
Figure 2
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